Following the unique synthesis of a massive compilation of data over a 10-year period, my research analytics have led to a groundbreaking perspective regarding fibromyalgia syndrome (FMS) and subsequent correctives. To date, this work has been entirely self-funded, up to and including the conception of patentable treatments with an equally patentable delivery method.
Although I have been cleared by Dr. Xibin Wang of the NAIDS to apply for the NIH Omnibus SBIR funding opportunity, which, with the participation of the FDA and CDC, would help me move my products from feasibility studies to market, there is a preliminary needs gap of $500K that must be addressed to file the product patents prior to submitting the NIH application.
To that end, I am prepared to submit an initial synopsis of my fibromyalgia analysis, should there be an interest in funding. Narrowed to four main points, it covers the source of chronic pain, the reason for premature aging, the development of autoimmunity, and the peripheral input that creates and thereafter sustains the path to central sensitization and therefore pain amplification.
Notwithstanding the fact that iron-overload is a novel and disruptive hypothesis, it relies on cold hard facts and is less divergent from the FMS literature than would seem to be implied.
It is, moreover, a comprehensive analysis, which examines the dysregulation of iron homeostasis via the liver and the mitochondria, the convergent and sometimes divergent impact of iron overload on the constantly moving, evolving, and interactively reactive behaviors of the musculofascial system, the neurological system, the neuroendocrine system, the immune system, and more. It also identifies new fibromyalgia markers that would greatly benefit people with chronic pain insofar as three out of four people with fibromyalgia are said to go undiagnosed.
Naturally, the work upholds the importance of exercise, naturopathic therapies, vitamin supplements, and nutrition. However, it also identifies key points for biochemical interventions that are sensitive enough to be context specific, both locally and from a whole-body perspective, under ever-changing conditions. It was therefore decided that a transdermal patch equipped with mechanosensing could assess certain bioactive processes and bioactive responses to administer the appropriate correctives on an as-needed basis directly in proportion to the actual threat levels and subsequent shifting conditions.
As you may know, fibromyalgia is predominantly a women's disease. What you may not know is that the global market for fibromyalgia treatment was predicted to grow from 3.1 billion in 2022 to 4.6 billion by 2032. Therefore, the impact of my products could foreseeably be enormous.
Thank you for your time and kind consideration.
Respectfully,
Jeanne M. Haskin
Ready to Ask For Funding for your company?
Post a Funding Request